Anti-Asthmatic Potential of Blungsu Ciplukan (Passiflora foetida L.) Leaf Extract in an Asthma Model in Mice

A report from the Ministry of Health of the Republic of Indonesia in 2018 revealed that the proportion of asthma recurrence within 12 months at all ages was still very high. It signifies that, so far, the therapy has not been effective. In fact, Passiflora foetida L. has the potential as an anti-asthma therapy since it contains apigenin, luteolin, and kaempferol and is easy to obtain. The method used in this research was quantitative experimental, with a post-test only design with a control group. The extraction technique employed was maceration. The test animals were made asthma models with lipopolysaccharide and ovalbumin for 17 days. Therapy was given on days 13-16. The negative control was given distilled water, while the positive control was given dexamethasone therapy. Then, lung histopathology was performed by assessing the degree of alveolar damage utilizing the Hansel and Barnes criteria. Alveolar edema, alveolar septal destruction, and inflammatory cell infiltration were then measured to demonstrate alveolar damage. The analysis results showed that the administration of Ciplukan Blungsu ( Passiflora foetida L. ) leaf extract gave a significant difference (p<0.05) to the histopathological description of the lung organs of the test animals. In conclusion, Ciplukan Blungsu ( Passiflora foetida L. ) leaf extract has a good asthma therapy effect.